IMRN vs INDP

Immuron Limited vs Indaptus Therapeutics, Inc. — Valuation Comparison 2026

IMRN

Pharmaceutical Preparations
Immuron Limited
Quality
1.7
out of 10
Value Trap
Price
$1.45
Last close
Models
7/13
Active
VS

INDP

Pharmaceutical Preparations
Indaptus Therapeutics, Inc.
Quality
2.5
out of 10
Value Trap
36
LOW
Price
$1.76
Last close
Models
4/13
Active

Model-by-Model Comparison

ModelType IMRN Fair ValueIMRN Upside INDP Fair ValueINDP Upside
Bayesian DCF Intrinsic $0.26 -81.8% $0.05 -97.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.70 +17.5% $0.21 -90.3%
Dynamic NAV Asset-Based $0.41 -71.6%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMRN vs INDP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMRN vs INDP — Which Stock Is More Undervalued?

INDP scores higher with a 2.5/10 quality rating vs IMRN's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Immuron Limited (IMRN) and Indaptus Therapeutics, Inc. (INDP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMRN currently trades at $1.45 with a QOC of 1.7/10, while INDP trades at $1.76 with a QOC of 2.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).